Stocks and Investing Stocks and Investing
Mon, March 2, 2020
Fri, February 28, 2020

Anupam Rama Maintained (SRPT) at Buy with Decreased Target to $160 on, Feb 28th, 2020


Published on 2024-10-26 22:52:14 - WOPRAI, Anupam Rama
  Print publication without navigation


Anupam Rama of JP Morgan, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $172 to $160 on, Feb 28th, 2020.

Anupam has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 0 agree with Anupam's Rating of Hold.



These are the ratings of the 7 analyists that currently disagree with Anupam


  • Alethia Young of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $217 on, Thursday, February 27th, 2020
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $173 on, Tuesday, December 24th, 2019
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $200 on, Monday, December 23rd, 2019
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $192 on, Friday, December 20th, 2019
  • Yun Zhong of "Janney Montgomery Scott" Maintained at Strong Buy with Increased Target to $175 on, Friday, December 13th, 2019
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Decreased Target to $167 on, Monday, November 18th, 2019
  • Whitney Ijem of "Guggenheim" Initiated at Strong Buy and Held Target at $183 on, Friday, November 1st, 2019
Contributing Sources